Novo Nordisk Wins Twin EMA Backing as Pipeline Data Tests Its Reliance on Semaglutide

Novo Nordisk shares drop 23% this year as revenue growth is set to slow, offsetting five planned launches and two EMA committee nods.

Novo Nordisk's shares have been under pressure even as its regulatory and clinical machinery keeps churning out wins. The Danish drugmaker closed at EUR 33.94 in the latest session, capping a bruising stretch in which the stock shed 10 percent over seven days and now sits 23 percent below where it started the year.

The divergence between operational momentum and market mood was on full display at the company's capital markets day in London, where management delivered a sobering medium-term outlook. Revenue growth between 2026 and 2030 is set to decelerate, with expansion rates converging toward the average of the large pharmaceutical manufacturers. Investors had been pricing in far more aggressive trajectories from the maker of obesity and diabetes treatments, and the guidance landed with a thud.

Five Launches Targeted by 2030

CEO Mike Doustdar used the Monday investor gathering to sketch out the response: a sweeping product offensive aimed at bringing at least five new medicines to market by 2030, each carrying blockbuster revenue potential. What the plan lacked, in the eyes of market participants, was any near-term catalyst capable of reigniting earnings momentum right away. Attention has consequently shifted toward clinical readouts on novel drug combinations.

Those readouts are already arriving. In the Phase 3 REIMAGINE 5 trial, the 1.0 mg/1.0 mg dose of CagriSema produced a 12.4 percent weight reduction in adults with type 2 diabetes after 60 weeks. Tirzepatide at 5 mg managed 9.1 percent over the same period, and the cagrilintide-semaglutide combination also demonstrated non-inferiority in lowering HbA1c.

Separately, the REDEFINE 9 study in adults with overweight or obesity showed an average 21 percent weight loss at week 68 compared with placebo. Novo Nordisk expects a US Food and Drug Administration decision on that front in the fourth quarter of 2026. Late-stage successes of this kind matter enormously for a company whose dependence on its existing flagship, semaglutide, is viewed across the industry as the single biggest risk to its valuation.

Morgan Stanley downgraded the stock to "Underweight" on September 11, estimating that semaglutide will account for roughly 75 percent of total revenue in 2026. Even when patent protection lapses — 2031 in Europe and 2032 in the United States — the bank projects the drug will still contribute 59 percent of sales.

Two Committee Nods in Two Days

Away from the obesity franchise, European regulators handed the company consecutive victories. The EMA's Committee for Medicinal Products for Human Use recommended FREHEMGO on September 17 for preventive treatment of haemophilia A in adults and children, with a European launch planned from the fourth quarter of 2026. The following day, the same committee backed Sogroya for children with idiopathic short stature and persistent growth disturbances. Should the European Commission grant approval, it would mark the first authorized therapy for that indication in the EU. A formal Commission decision covering three indications is expected before year-end.

Both recommendations bolster Doustdar's strategy of broadening the portfolio beyond existing GLP-1 treatments.

Buybacks as a Backstop

With the share price subdued, management is deploying capital to support the stock. Under a DKK 15 billion repurchase program, the group had bought back more than 34 million B shares since early February, at an average price of DKK 281.79 per share. As of September 18, the company had spent over DKK 9.6 billion on its own B shares since February.